[1]曾雅琳,李鑫,胡世弟,等.FRAX对骨质疏松性骨折防治的利与弊[J].国际内分泌代谢杂志,2014,(01):67-72.[doi:10.3760/cma.j.issn.1673-4157.2014.01.019]
　Zeng Yalin*,Li Xin,Hu Shidi,et al.The benefits and limitations of FRAX in prevention of osteoporotic fracture[J].International Journal of Endocrinology and Metabolism,2014,(01):67-72.[doi:10.3760/cma.j.issn.1673-4157.2014.01.019]
点击复制

FRAX对骨质疏松性骨折防治的利与弊()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年01期
页码:
67-72
栏目:
综述
出版日期:
2014-02-28

文章信息/Info

Title:
The benefits and limitations of FRAX in prevention of osteoporotic fracture
作者:
曾雅琳; 李鑫; 胡世弟; 戴如春
410011　长沙,中南大学湘雅二医院代谢内分泌研究所（曾雅琳,胡世弟,戴如春）；411100　湘潭市第二人民医院内分泌科（李鑫）
Author(s):
Zeng Yalin*; Li Xin; Hu Shidi; Dai Ruchun.
*Institute of Metabolism and Endocrinology,The Second Xiangya Hospital of Central South University,Changsha 410011,China Corresponding author：Dai Ruchun,Email：dairuchun@qq.com
关键词:
FRAX; 骨质疏松性骨折; 骨密度
Keywords:
FRAX; Osteoporotic fracture; Bone density
DOI:
10.3760/cma.j.issn.1673-4157.2014.01.019
摘要:
骨折危险因子评估（FRAX）是世界卫生组织最新推出的预测骨折危险的评估工具。根据FRAX,低骨量和10年内髋骨骨折≥3%或骨质疏松引起的主要骨折≥20%的患者,应及时进行药物干预。其作为一种在全球大量荟萃分析基础上建立的网络评估工具,易于获取,并能简便有效的帮助临床医生判断出需要药物治疗的患者。然而,FRAX也受某些因素的限制,如没有考虑跌倒等骨折独立危险因子、没有重视剂量-效应关系、不能对已经接受治疗的患者进行评估、不能监测治疗效果等。目前FRAX不能代替已有的临床危险评估方法,还需进一步完善。
Abstract:
Fracture risk factor assessment （FRAX） is the latest assessment tool for fracture risk which is recommended by World Health Organization.According to it,patients with low bone density and hip fracture of ≥3% or a ≥20% ten-year risk of a major osteoporosis-related fracture should be treated with drug timely.FRAX is an assessment model which is based on a series of meta-analysis around the world,as a network tool,it is easy to obtain and can help physicians to identify the patient who need a treatment effectively.However,FRAX is also limited by some factors,it does not take into account some independent risk factors for fracture such as falls and it does not pay attention to dosage-effect relationships as well.FRAX may only be used in untreated patients and it can not monitor the effect of treatment and so on.At present, FRAX can not take place of the existing clinical assessment methods,it still need to be perfected further.

参考文献/References:

　[1]　Silverman SL,Calderon AD．The utility and limitations of FRAX： A US perspective[J]．Curr Osteoporos Rep,2010,8（4）：192-197. 　
[2]　赵红燕,刘建民．骨折风险评估工具FRAX的临床应用[J]．诊断学理论与实践,2012,11（1）：21-24. 　
[3]　van den Bergh JP,van Geel TA,Lems WF,et al．Assessment of individual fracture risk：FRAX and beyond[J]．Curr Osteoporos Rep,2010,8（3）：131-137. 　
[4]　Watts NB．The Fracture Risk Assessment Tool （FRAX（Ｒ））：applications in clinical practice[J]．J Womens Health（Larchmt）,2011,20（4）：525-531. 　
[5]　Zhang Z,Ou Y,Sheng Z,et al．How to decide intervention thresholds based on FRAX in central south Chinese post-menopausal women[J]．Endocrine,2013,[Epub ahead of print]. 　
[6]　Alzahouri K,Bahrami S,Durand-Zaleski I,et al．Cost-effective-ness of osteoporosis treatments in postmenopausal women using FRAXTM thresholds for decision[J]．Joint Bone Spine,2013,80（1）：64-69. 　
[7]　Kanis JA,Johnell O,Oden A,et al．FRAX and the assessment of fracture probability in men and women from the UK[J]．Osteoporos Int,2008,19（4）：385-397. 　
[8]　Kanis JA,Oden A,Johansson H,et al．FRAX and its applications to clinical practice[J]．Bone,2009,44（5）：734-743. 　
[9]　Trémollieres FA,Pouillès JM,Drewniak N,et al．Fracture risk prediction using BMD and clinical risk factors in early post-menopausal women: sensitivity of the WHO FRAX tool[J]．J Bone Miner Res, 2010,25（5）：1002-1009.
[10]　Bauer DC．FRAX,falls,and fracture prediction：predicting the future[J]．Arch Intern Med,2011,171（18）：1661-1662.
[11]　Schwartz AV,Vittinghoff E,Bauer DC,et al．Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes[J]．JAMA,2011,305（21）：2184-2192.
[12]　Giangregorio LM,Leslie WD,Lix LM,et al．FRAX underesti-mates fracture risk in patients with diabetes[J]．J Bone Miner Res,2012,27（2）：301-308.
[13]　Lewiecki EM,Watts NB．New guidelines for the prevention and treatment of osteoporosis[J]．South Med J,2009,102（2）：175-179.
[14]　Watts NB,Ettinger B,LeBoff MS．FRAX facts[J]．J Bone Miner Res,2009,24（6）：975-979.
[15]　Gehlbach S,Saag KG,Adachi JD,et al．Previous fractures at multiple sites increase the risk for subsequent fractures：the Global Longitudinal Study of Osteoporosis in Women[J]．J Bone Miner Res,2012,27（3）：645-653.
[16]　McClung MR．To FRAX or not to FRAX[J]．J Bone Miner Res,2012,27（6）：1240-1242.
[17]　Leslie WD,Lix LM,Johansson H,et al．Does osteoporosis therapy invalidate FRAX for fracture prediction?[J].J Bone Miner Res,2012,27（6）：1243-1251.
[18]　Donaldson MG,Palermo L,Ensrud KE,et al．Effect of alen-dronate for reducing fracture by FRAX score and femoral neck bone mineral density：the Fracture Intervention Trial[J]．J Bone Miner Res, 2012,27（8）：1804-1810.
[19]　Kanis JA,Johansson H,Oden A,et al．A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX[J]．Bone,2010,47（4）：729-735.
[20]　González-Macías J,Marin F,Vila J,et al．Probability of fractures predicted by FRAX　and observed incidence in the Spanish ECOSAP Study cohor[J]．Bone,2012,50（1）：373-377.
[21]　Gadam RK,Schlauch K,Izuora KE．Frax prediction without BMD for assessment of osteoporotic fracture risk[J]．Endocr Pract,2013,19（5）：780-784.
[22]　Adams JE．Advances in bone imaging for osteoporosis[J]．Nat Rev Endocrinol,2013,9（1）：28-42.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目（81070695,81270960）；教育部“新世纪优秀人才支持计划”（NCET-11-0507） 　　通信作者：戴如春,Email:dairuchun@qq.com
更新日期/Last Update: 2014-01-20